Abstract
Background . Lung cancer is one of the most common cancers worldwide. Most newly diagnosed lung cancer patients present with distant metastases. Objective : to demonstrate a successful clinical case showing longterm overall and relapse-free survival rates in a patient with disseminated non-small cell lung cancer treated with a combination of immunotherapy and chemotherapy. Case presentation . A 72-year-old patient diagnosed with stage IV (T1bN0M1b) non-small cell lung asenocarcinoma of the right upper lobe achieved long-term disease stabilization using a combination of atezolizumab, bevacizumab and chemotherapy. The overall and progression-free survival was 38 months with a favorable safety profle. Conclusion . Despite current drug therapy options, the treatment of metastatic NSCLC remains challenging. This case report demonstrates the effcacy of atezolizumab in combination with bevacizumab and chemotherapy in patients with metastatic, untreated EGFR- and ALK -negative NSCLC negative for programmed cell death ligand 1 (PD-L1).